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a  b  s  t  r  a  c  t
Acrylamide  is  known  to produce  follicular  cell  tumors  of the  thyroid  in  rats.  RccHan  Wistar  rats  were
exposed  in  utero  to a  carcinogenic  dose  of  acrylamide  (3 mg/Kg  bw/day)  from  gestation  day  6  to  delivery
and  then  through  their  drinking  water to postnatal  day  35. In order  to  identify  potential  mechanisms
of carcinogenesis  in  the  thyroid  glands,  we used  a transcriptomics  approach.  Thyroid  glands  were  col-
lected  from  male  pups  at 10 PM  and female  pups  at  10  AM  or 10 PM  in  order  to establish  whether  active
exposure  to acrylamide  inﬂuenced  gene  expression  patterns  or  pathways  that  could  be related  to carcino-
genesis.  While  all animals  exposed  to acrylamide  showed  changes  in  expected  target  pathways  related
to carcinogenesis  such  as  DNA  repair,  DNA  replication,  chromosome  segregation,  among  others;  animals
that were  sacriﬁced  while  actively  drinking  acrylamide-laced  water  during  their active  period  at  night
showed  increased  changes  in pathways  related  to  oxidative  stress,  detoxiﬁcation  pathways,  metabolism,
and  activation  of checkpoint  pathways,  among  others.  In  addition,  thyroid  hormones,  triiodothyronine
(T3)  and  thyroxine  (T4),  were  increased  in  acrylamide-treated  rats  sampled  at  night,  but  not  in  quiescent
animals  when  compared  to controls.  The  data  clearly  indicate  that  time  of day  for  sample  collection  is
critical  to identifying  molecular  pathways  that  are  altered  by the  exposures.  These  results  suggest  that
carcinogenesis  in the  thyroids
such  as  hormonal  changes  and 
to date.
© 2016  The  Authors.  Pu
Abbreviations: ADA, adenosine Deaminase; ADRB2, adrenergic; ASF1B, anti-Silencin
elicase 1; BUB1B, BUB1 Mitotic Checkpoint Serine/Threonine Kinase B; C1QTNF3, C1
ALCR,  calcitonin receptor; CARD9, caspase recruitment domain family; CCNA2, cyclin A
DC45,  cell division cycle 45; CDCA2, cell division cycle associated 2; CDCA5, cell divis
GA,  glycoprotein hormones; CTLA4, cytotoxic T-lymphocyte-associated protein 4; DAD1
cytosine-5-)-methyltransferase 3 alpha; DUOX2, dual oxidase 2; GCG, glucagon; GCLC, gl
;  GSTP1, glutathione S-transferase Pi 1; HPSE, heparanase; HSPA5, heat shock 70 kDa p
SPH1,  heat shock 105 kDa/110 kDa protein 1; HTATIP2, HIV-1 tat interactive protein 2;
);  IL1B, interleukin 1; INHBA, inhibin; IYD, iodotyrosine deiodinase; KIF20B, kinesin fa
aminin, alpha 2; MCM8, minichromosome maintenance complex component 8; MIF, mac
DC80 kinetochore complex component; NPPC, natriuretic peptide precursor C; NPY, neu
DE3A,  phosphodiesterase 3A; PINK1, PTEN induced putative kinase 1; PLCD1, phospholip
rostaglandin I2 (prostacyclin) synthase; PTGS1, prostaglandin-endoperoxide synthase 
as-related nuclear protein; RRM2, ribonucleotide reductase M2; SCL5A5, solute carrier
40  kDa; SPAG8, sperm associated antigen 8; TACC3, transforming; TBCB, tubulin folding
hyroid peroxidase; TSHR, thyroid stimulating hormone receptor; TSN, translin; VWF, Vo
∗ Corresponding author at: University of Florida & Center for Environmental and Huma
E-mail  addresses: rcolli.dula@mda.cinvestav.mx (R.C. Collí-Dulá), killrat2005@gmail.c
N.D. Denslow).
1 Current address: CONACYT Research Fellow, Departamento de Recursos el Mar, Centr
érida,  Mexico.
ttp://dx.doi.org/10.1016/j.toxrep.2016.03.009
214-7500/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/). of  acrylamide  treated  rats  may  ensue  from  several  different  mechanisms
oxidative  stress  and  not  only  from  direct  genotoxicity,  as has  been  assumed
blished  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
g Function 1B Histone Chaperone; BRIP1, BRCA1 Interacting Protein C-Terminal
q and Tumor Necrosis Factor Related Protein 3; C5, complement Component 5;
2; CCNG1, cyclin G1; CD45, protein tyrosine phosphatase; CD46, CD46 molecule;
ion cycle associated 5; CENPT, centromere protein T; CFB, complement factor B;
, defender against cell death 1; DCTPP1, DCTP pyrophosphatase 1; DNMT3A, DNA
utamate-cysteine ligase; GOLGA3, golgin A3; GSTM1, glutathione S-transferase Mu
rotein 5; HSPB1, heat shock 27 KDa protein; HSPB2, heat shock 27 kDa protein 2;
 ID1, inhibitor of DNA binding 1; IGF2, Insulin-like growth factor 2 (somatomedin
mily member 20B; KIF22, kinesin family Member 22; KLK1, kallikrein 1; LAMA2,
rophage migration inhibitory factor; MIS18A, MIS18 kinetochore protein A; NDC80,
ropeptide; NUBP1, nucleotide binding protein 1; ORC1, origin recognition complex;
ase C; PLK1, polo-like kinase 1; POMC, proopiomelanocortin; PRL, prolactin; PTGIS,
1; PRKAA2, protein kinase; PRODH, proline dehydrogenase; RAB5A, RAB5A; RAN,
 family 5 (sodium iodide symporter); SELP, selectin P (granule membrane protein
 cofactor B; TFRC, transferrin receptor; TOP2A, topoisomerase (DNA) II alpha; TPO,
n Willebrand Factor.
n Toxicology, P.O. Box 110885, Gainesville, FL 32611 USA.
om (M.A. Friedman), lpt@lpt-Hamburg.de (B. Hansen), ndenslow@uﬂ.edu
o de Investigación y Estudios Avanzados del Instituto Politécnico Nacional, Unidad





























































sR.C. Collí-Dulá et al. / Toxic
. Introduction
Acrylamide (AA) is a monomer used in the manufacture of poly-
ers for mining, oil and natural gas processing, paper manufacture,
aste processing, hospital laboratories, among other uses. Adverse
ealth effects from worker exposure to AA have been extensively
tudied [44]. No adverse effects have been reported with daily
uman exposure up to 2.1 mg/kg/day [19]. Exposure to AA in food-
tuffs has become a worldwide concern because of its generation
n a variety of carbohydrate rich foods when these are cooked
t temperatures exceeding 120 ◦C. At these temperatures, AA is
ade from the Maillard reaction of sugars with asparagine residues
24,55].
The World Health Organization (WHO) and Food and Agricul-
ure Organization [22], the Environmental Protection Agency [18],
nd the European Food Safety Authority [16] have classiﬁed AA
s a “probable human carcinogen” by virtue of its conversion to
lycidamide, as the ultimate carcinogen in rodents. In vivo, AA is
etabolized by CYP 2E1 to glycidamide (an epoxide), which also
s very reactive toward nucleophiles and has been implicated in
dduct formation at active site cysteines of proteins and the amino
erminus of hemoglobin and also with nucleic acids [24,47]. Only a
ortion of the AA gets converted to glycidamide. The classiﬁcation
s a probable human carcinogen is based primarily upon repro-
ucible carcinogenicity studies in Fischer rats [2,26,34]. Tumors
ere observed in the mammary gland (ﬁbroadenomas), thyroid
follicular tumors) and tunica vaginalis testes in rats [2,26,33].
hese tumor sites have well documented rat-speciﬁc modes of
ction, which are not relevant to humans [3,31,56,59].
Thyroid follicular tumors can arise in rats speciﬁcally from
hemical disturbance of thyroid-pituitary homeostasis, or from a
ombination of genotoxicity and hormonal alterations. External
actors that change thyroid hormone metabolism result in a marked
hange in thyroid behavior in rats [36]. AA treatment for 7, 14 or
8 days results in increased mitotic ﬁgures and Dﬁgures and DNA
ynthesis in the thyroids of Fischer rats [43]. The Fischer rat has a
nique hormonal milieu that may  be responsible for these tumors.
owever, speciﬁc changes in thyroid transcriptomics have yet to be
ocumented. It has been suggested that alteration of the dopamine
eceptor is responsible for the change in thyroid metabolism [65].
A also causes oxidative stress in rats [72] and the thyroid has a
ery high oxidation level [72,73].
AA is mutagenic in rats and mice [12]. This mutagenic proﬁle
oes not ﬁt the pattern of tumors observed in Fischer rats, as the
peciﬁcity cannot be explained [27,52,65,74]. AA is a very weak
arcinogen and mutagen [74]. Since mutagenicity is the regulatory
efault assumption as a mechanism for carcinogenicity, use of other
echanistic data for regulatory purposes has been limited. In con-
rast to the Fischer rat, the only signiﬁcant tumors observed in male
istar rats were in the thyroid gland [51]. While thyroid tumors
n rats are not considered to be relevant to humans, mechanisms
or genotoxicity in the thyroid still represent a possible signiﬁcant
isk. This study was designed to build upon the large volume of data
ublished to date about AA exposure of rats to determine whether
umors formed in the thyroid after chronic exposure to AA were
roduced only through a genotoxic component.
The research conducted here determines the effect of AA
n gene expression in weanling Wistar rat thyroids following
n utero exposure to a carcinogenic dose of AA. This research
s intended to differentiate between DNA reactivity, oxidative
tress and direct action on hormone receptors. A transcriptomics
pproach (microarrays and bioinformatics) was used to investigate
hanges in gene expression and the association with physiologi-
al responses (changes in plasma hormone levels) in rats treated
ith AA from gestational day 6 to post-natal day 35. We hypothe-
ized that 3 mg  AA/Kg bw/day exposure would produce changes inReports 3 (2016) 414–426 415
plasma hormone levels associated with key genes and biochemical
pathways involved with molecular actions of AA.
2. Materials and methods
2.1. Test material
AA (C3H3NO, CAS no 79-06-1, 1,2-propenamide; >99.9% pure;
Sigma Aldrich) was  dissolved in tap water and evaluated for sta-
bility at room temperature at 6, 13, 20, and 27 test days after
preparation. Recovery ranged from 96.9% to 102.6%.
2.2. Animal exposures
The methods used to conduct this study have been previously
published [51]. The in vivo phase of this study was conducted under
GLP guidelines and was externally audited. It was approved by
the responsible local government ofﬁce according to the German
animal welfare law “Tierschutzgesetz” (TierSchG). AA solutions
were prepared weekly and concentrations were adjusted for body
weight. Water bottles were changed weekly. AA concentration in
the drinking water was determined at test week 4 and 10.
Sperm positive female Wistar HanTM/RccHanTM:WIST rats were
obtained from Harlan Laboratories GmbH, Serumweg 48, 27324
Eystrup, Germany in multiple deliveries. At gestation day 6, dams
were provided AA in their drinking water. Exposures continued in
F1 offspring through postnatal day (pnd) 35 ± 3. Rats were housed
1 per cage in MACROLON cages with granulated wood bedding
(Brandenburg, 49424 Goldenstedt/Arkeburg). Animal rooms were
alternately lit (about 150 lx at approximately 1.50 m room height)
and darkened in a 12-hour lighting cycle. Cage side observations
were conducted twice per day during the week and once per day
on weekends.
On day 4 after birth, the weights of the pups were determined.
The size of each litter was  adjusted by eliminating extra pups to
yield, as nearly as possible, ﬁve males and ﬁve females per litter and
remaining animals remained with the dams until day 21 of lactation
(weaning). On lactation day 21, the F1 animals were randomized
using a computer randomization program to assign the animals to
the subsets within each group.
A separate cohort of the animals was allowed to continue on
the same regimen for two  years. At the end of the two years, mam-
mary gland ﬁbroadenomas were identiﬁed in females and thyroid
follicular cell tumors were identiﬁed in both sexes [51].
2.3. Plasma TSH, T3 and T4 analysis
On pnd 35 ± 3, at approximately 10 AM and 10 PM,  respectively,
as much blood as possible was withdrawn from 5 male and 5 female
F1 rats/dose. The thyroids were removed and frozen. Blood sam-
ples were divided into 5 aliquots. Four aliquots of at least 75 L
were frozen and stored at −20 ◦C. Two aliquots were analyzed using
the rat pituitary panel from Millipore for adrenocorticotropic hor-
mone (ACTH), brain-derived neurotrophic factor (BDNF), growth
hormone (GH), follicle-stimulating hormone (FSH), luteinizing hor-
mone (LH), and prolactin. Then two aliquots were analyzed using
the rat thyroid milliplex kit from Millipore for T3, T4 and TSH.
2.4. Extraction of total RNA and RNA quality control
Total RNA was  extracted from the thyroid gland of rats (n = 4; 4
controls and 4 AA-treated per tissue) using RNA STAT-60 reagent
(Tel-Test Inc., Friendswood, TX, USA) according to the manufac-
turer’s instructions. A total of 500 ng of RNA was  DNase-treated
with Turbo DNA-free (Ambion Austin, TX) following the man-
ufacturer’s protocol. RNA quantity for microarray analysis was
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uig. 1. Plasma levels of thyroid hormones and TSH in animals collected in the mo
nimals sampled at night with (A, B) TSH; (C, D) T3; and (E, F) T4. Box plots indicat
ithin box). Whiskers represent the highest and lowest points. Different letters ind
roup); MM (male morning); FM (female morning); MN (male night); FN (female n
easured using the NanoDrop ND-1000 (Nanodrop Technologies,
ilmington, DE) and RNA quality was evaluated using the Agilent
100 BioAnalyzer with the RNA 6000 Nanochip. RNA integrity val-
es (RIN) were >8.0 for all samples used in the analysis. Total RNA
as used for microarray analysis and real-time quantitative PCR
qPCR)..5. Microarray analysis
Gene expression patterns of thyroid samples were identiﬁed
sing the Rat V1 8 × 60 K oligonucleotide microarray manufacturedand at night (n = 5 per group). (A, C, E) Animals sampled in the morning; (B, D, F)
pper and lower percentile (10–90th) and the median values (horizontal black line
igniﬁcant differences among groups. CTRL (control group); AA (Acrylamide-treated
by Agilent (Palo Alto, CA, USA). 100 ng of total RNA per sam-
ple (n = 4 biological replicates for each condition) were used for
the analysis following the manufacturer’s kits and protocols (Agi-
lent Low input Quick-amp labeling kit one color; Agilent, Santa
Clara, CA, USA). All samples used for microarrays contained a
speciﬁc activity >9.0 pmol Cy3/ml and amounts were adjusted to
a ﬁnal mass of 600 ng. Microarrays were kept in the dark until
scanning using an Agilent G2505B microarray scanner. Data extrac-
tion was performed using Agilent Feature Extraction software (v
9.5). All microarrays were submitted to NCBI’s Gene Expression
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ccession number (GSE 62026). We  had technical issues with sam-
les from male rats collected in the morning and for this reason,
hese results are not being presented here.
.6. Bioinformatics
The microarray data were analyzed independently by two dif-
erent groups using JMP  Genomics v5 (SAS, Cary, NC, USA) and
y open source R-based software packages. The microarrays were
erformed in two different batches, one year apart, and it was
mpossible to analyze both batches in one ANOVA because of sig-
iﬁcant batch effects. Thus, each of the batches was analyzed
eparately and comparisons at the pathway level were possible
etween the two batches.
In JMP  Genomics, raw expression data were log2-transformed
nd all control and non-uniform spots were removed prior to the
nal analysis. All probe responses per gene were averaged before
sing median normalization. One-way ANOVA was used to ﬁnd
enes that were signiﬁcantly altered (p < 0.05; fold change greater
han ±1.2). The list of genes from the ANOVA was subjected to
ierarchical clustering for each batch of arrays independently. The
rrays were also analyzed by other non-parametric algorithms
ncluding Gene Set Enrichment Analysis (GSEA) [69] and Fischer
xact Test with the Sub-Network Enrichment Analysis (SNEA) [40]
vailable through PathwayStudioTM (Elsevier Inc., Philadelphia, PA,
SA), described in more detail below.
The second analysis used R-based software packages in a step-
ise process consisting of a quality assessment of the array data,
rocessing of the arrays for background correction and group
ormalization, unsupervised clustering, and class comparison for
ifferential expression. The software components required to exe-
ute the source code include the following: (1) R environment
or statistical programming (R package Limma) [67]; (2) Several
ackage libraries from BioConductor [35]; (3) R markdown text
ormatting system; and (4) Knitr engine for dynamic report gen-
ration with R. Statistical criteria for identiﬁcation of differentially
xpressed genes were false discovery rate (FDR) adjusted P* < 0.05
nd fold change greater than 1.5. Based upon these ﬁlter crite-
ia no differential gene expression was observed between animals
xposed to AA and controls. Further analysis with FDR adjusted
* < 0.10 resulted in 1 gene being differentially expressed between
A treated animals and controls (Slc35b1, log FC = 1.6, P* = 0.05,
olute carrier family 35, member B1).
.7. PathwayStudioTM analysis
Pathway StudioTM V9 (operating with the ResNet 9.0 database)
as used to identify molecular pathways associated with chronic
oxicity of AA. Speciﬁcally two datasets were generated using (1)
isher’s Exact Test with (p-value < 0.05) and SNEA and (2) GSEA,
sing the Kolmogorov-Smirnov test (p < 0.05) [40,69]. GSEA is an
nalytical method used to evaluate microarray data at the level of
ene sets, which are deﬁned based on prior biological knowledge
f gene ontology and curated pathways [40,69].
.8. Quantitative real-time PCR (qPCR)
Quantitative reverse transcriptase polymerase chain reaction
qPCR) was performed in order to conﬁrm some of the results of
ifferential gene expression identiﬁed by microarray analysis. We
elected ﬁve different genes for the morning animals and ﬁve for
he night animals and used TaqMan probes designed and validated
y Applied Biosystems (Foster City, CA, USA). Gene symbols and ID
f the TaqMan assays used are identiﬁed in Table 1.
We  used the same total RNA as used for microarrays. First-strand
DNA was synthesized from 250 ng DNAse treated total RNA usingReports 3 (2016) 414–426 417
250 ng random primers and SuperScriptTM II Reverse Transcriptase
(Invitrogen/Life Technologies, Grand Island, NY, USA) in a 20 L
reaction, as per the manufacturer’s protocol. qPCR analysis was
performed in an ABI 7500 Fast System instrument (Applied Biosys-
tems, Foster City, CA, USA). In brief, a mixture was  made with 1 L
cDNA template (diluted to 100 ng/L), 0.5 L of each probe from the
speciﬁc TaqMan assay (20X), 1 L of a 2X TaqMan Fast Advanced
master mix and 3 L Nuclease-free water in 10 L total volume per
reaction, as indicated in the manufacturer’s protocol. TaqMan PCR
cycling conditions were set at 95 ◦C for 20 s for the ﬁrst cycle and
3 s at 95 ◦C followed by 30 s at 60 ◦C for the remaining 40 cycles,
as indicated in the manufacturer’s protocol. All experimental sam-
ples were run in duplicate, along with two  negative controls; a
“no reverse transcriptase (-RT)” control, in which DNase-treated
RNA samples were pooled and water was used in place of reverse
transcriptase during the reverse transcription reaction, and a “no
template control (NTC), ” in which water was used in place of tem-
plate cDNA during the real-time PCR reaction. 18S ribosomal RNA
was used as the reference gene to normalize expression data. The
results were analyzed using the Ct method of relative quantiﬁ-
cation [45].
2.9. Statistical analyses
Signiﬁcant differences in plasma levels of hormones in AA
treated animals were determined using one-way analysis of vari-
ance (ANOVA) followed by a Tukey’s Test. For qPCR a t-test was
performed on normalized gene expression to evaluate whether
the expressions were statistically different compared to controls
(p < 0.05).
For both plasma hormone levels and qPCR when data were not
normally distributed, the Kruskal–Wallis non-parametric test was
followed by the Mann-Whitney U-test. A p-value ≤0.05 was con-
sidered statistically signiﬁcant. Statistical analyses were performed
using Sigma Plot (SYSTAT, Chicago, IL, USA) and ﬁgures were plotted
using Prism 5.0 (GraphPad Software Inc., San Diego CA).
3. Results
3.1. Phenotypic anchoring: measurement of plasma hormones in
treated and control rats
Changes in plasma hormone concentrations in pnd 35 rats
occurred mainly in nocturnal animals of both sexes. Male rat plasma
collected at night showed signiﬁcant increases in T4, T3 and pitu-
itary ACTH by 87%, 24.6% and 223%, respectively compared to
controls. In females collected at night, plasma TSH was  reduced
by 44.7% and T4 and T3 were increased by 84.6% and 20.2%, respec-
tively, compared to controls. The changes in T3 and T4 levels in
female and male rats sampled at night closely matched each other
(Fig. 1). Prolactin was only decreased in male rats sampled in the
morning with levels decreased by 76% (data not shown). Other hor-
mones tested were not signiﬁcantly altered in any of the animals.
Interestingly, only night animals showed changes in genes
related to thyroid hormone biosynthesis and function. Genes per-
taining to this pathway that were changed in males sampled at
night are shown in Fig. 2. Fewer genes in this pathway were changed
in females sampled at night.
3.2. Gene expression changes in male and female ratsMicroarray analysis was performed separately on thyroids of
animals collected in the morning or at night. ANOVA results indi-
cated a large number of differentially regulated genes for rats
exposed to AA. Male rat thyroids collected at night exhibited 1800
418 R.C. Collí-Dulá et al. / Toxicology Reports 3 (2016) 414–426
Table 1
Genes selected for conﬁrmation by qPCR.
Night group genes
Gen bank Accession Gene Name Gene Symbol IDa
NM 022303 Caspase recruitment domain family, member 9 Card9 Rn00673582 m1
NM  012547 Dopamine receptor D2 Drd2 Rn00561126 m1
NM  080906 DNA-damage-inducible transcript 4 Ddit4 Rn01433735 g1
NM 019353 Thyroid peroxidase Tpo Rn00571159 m1
NM  001009623 Tumor necrosis factor (ligand) superfamily, member 13 Tnfsf13 Rn01467490 g1
Morning group gene
NM 053749 Aurora kinase B Aurkb Rn01460656 m1
NM  024141.1 Dual oxidase 2 Duox2 Rn01514628 m1
NM  001106335.1 Inner centromere protein Incenp Rn01478880 g1
NM 139326.2 Proopiomelanocortin Pomc Rn00595020 m1
NM 022183 Topoisomerase (DNA) II alpha Top2a Rn00573347 m1
Normalizing Gene
NR 046239.1 45S pre-ribosomal RNA 
a TaqMan assays ID (Applied Biosystems).
Fig. 2. Changes in gene expression that were related to thyroid hormone gener-
ation and thyroid function in male rats sampled at night. Pathways were built
by  sub-networks enrichment analysis (p-value >0.05; fold change > ± 1.2; statis-



















iown-regulation of gene expression; red, up-regulation; and yellow indicates the
rocesses likely affected. Color intensity correlates with the degree of response. The
bbreviations of the genes are listed in the abbreviations list.
ltered genes (1157 up-regulated and 642 down-regulated). With
n FDR correction of 10%, only one gene (solute carrier family 35,
ember B1 (Slc35b1) was signiﬁcantly altered in this group. There
ere procedural issues for the microarrays for males collected in
he morning and for that reason the results are not presented here.
Female thyroids sampled at night presented 2221 genes (1155
p-regulated and 1066 down-regulated), whereas female thyroids
ollected in the morning presented 2793 genes (854 up-regulated
nd 1939 down-regulated). Application of a FDR at 5% showed no
ltered genes. In order to get pathway information, we  broadened
he criteria to include genes that were altered with a p value <0.05
nd fold expression > ±1.2 and an FDR was not applied. Changes in
ene expression are shown in Table SI-1.
The differentially regulated transcripts were ordered according
o their fold-expression levels in males sampled at night (MN) fol-
owed by their expression levels in females sampled at night (FN),
nd then females sampled in the morning (FM) (Fig SI-1), keep-
ng the same order of genes. This evaluation showed that many18S Rn03928990 g1
genes were signiﬁcantly altered in the same direction in both male
and female samples collected at night, but some of these same
genes were altered in different directions in females collected in
the morning. A partial list of these common genes can be found in
Table 2.
These genes are involved in processes including, xenobiotic
metabolism, motor proteins, oxidative stress, and cell cycle check-
point pathways, among others. Genes that were commonly altered
in females collected in the morning and at night are presented in
Table 3. Remarkably, females collected in the morning also showed
a large group of altered genes that were not altered in animals col-
lected at night. Some of these genes are in the same families as
genes altered at night and their non-correspondence may  be due
to the use of different microarrays for these analyses. Thus, the best
way to jointly analyze these data is at the pathway level rather than
at the speciﬁc gene level.
3.3. Common alterations of the transcriptome for rats of both
genders
The genes selected by ANOVA were used for SNEA. Several sub-
networks were common to all of the animals tested (Table 4).
Common pathways altered in both males and females at the lowest
p values (<8.0E-07) included cell proliferation, cell differentiation,
apoptosis, cell death, cell migration, cell growth, cell cycle, pro-
tein folding, and myogenesis, among others. The top 100 predicted
pathways via SNEA for animals sampled at night males had a p value
<0.002 for males and <0.009 for females (Table SI-2). However, it
is clear from Table 5 that the top gene sets altered in females sam-
pled at night were different from those altered in females in the
morning.
When both genders were analyzed together for this time point,
the top 12 common pathways altered were cell death, apoptosis,
protein folding, kinetochore assembly, decidualization, pregnancy,
colorectal motility, muscle development, eating behavior, response
to heat shock, oocyte development and heart function (p value
<0.0008) (Table SI-3A). When females from the night and morning
sampling times were analyzed together to ﬁnd common pathways,
the top pathways included DNA replication, apoptosis, cell growth
and cell proliferation, among others (Table SI-3B).
The lists of genes from the microarray analysis were also
subjected to a non-parametric statistical analysis, GSEA, which pro-
vided additional pathway information. An analysis for pathways
for all three groups yielded 10 cellular processes that were com-
monly altered with DNA replication heading the list (Table 6).
When considering only animals sampled at night, there were
20 common pathways, including INO80Chromatin Remodeling,
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Table  2
Partial list of transcripts from males and females collected at night that were most changed including those encoding processes involved with thyroid hormone generation,
processing and protein transport, motor proteins, detoxifying enzymes, transcripts involved in oxidative stress, and checkpoint pathways involved in cancer.
Probe Name Gen bank Accession Gene Symbol Gene Name Fold Change (p ≤ 0.05)
Male Female
Thyroid hormone
A 64 P076450 NM 139326 Pomc Proopiomelanocor-tin 18.4 6.3
A  64 P155193 NM 021653 Dio1 Deiodinase, iodothyronine, type I 1.4 1.6
A  42 P625922 NM 012547 Drd2 Dopamine receptor 5.2 2.4
A  44 P238257 NM 053920 Trip10 Thyroid hormone receptor interactor 10 −1.5 −1.3
Processing and protein transport
A 43 P16457 NM 001037208 Creld2 Cysteine-rich with EGF-like domains 2 2.2 2.1
A 64 P056846 NM 012815 Gclc Glutamate-cysteine ligase, catalytic subunit 2.0 1.4
A 64 P021433 NM 001007755 Scly Selenocysteine lyase 1.7 1.3
Motor proteins
A 42 P757258 NM 001107609 Kif20b Kinesin family member 20B 1.8 1.3
A  64 P108200 NM 001009645 Kif22 Kinesin family member 22 1.7 1.2
A  64 P111749 XM 001057533 Kif2a Kinesin family member 2A 1.7 1.9
A  44 P163018 NM 001009619 Nubp1 Nucleotide binding Protein 1 1.3 1.2
A  44 P463313 NM 017100 Plk1 polo-like kinase 1 1.5 1.3
A  44 P213149 NM 001107369 Mastl Microtubule associated serine/threonine kinase-like 2.3 1.6
Detoxifying enzymes/Oxidative Stress
A 64 P137037 NM 017156 Cyp2b12 Cytochrome P450, family 2, subfamily b, polypeptide 12 1.4 2.0
A  64 P004231 NM 001159739 Gsta5 Glutathione S-transferase Yc2 subunit 2.5 1.5
A  42 P678430 NM 022303 Card9 Caspase recruitment domain family, member 9 1.6 1.4
A  64 P119916 NM 024141 Duox2 Dual oxidase 2 1.7 1.2
A  64 P095830 NM 152242 Gpr56 G protein-coupled receptor 56 1.6 1.3
A  42 P636627 NM 017110 Cartpt CART prepropeptide 1.6 2.4
A  64 P069374 NM 017247 Scn10a Sodium channel, voltage-gated, type X, alpha 3.1 1.9
A 64 P035564 NM 001108682 Tlr12 Toll-like receptor 12 1.6 1.8
Checkpoint pathways and cancer
A 64 P012009 NM 001106787 Mov10L1 Mov10L1, Moloney leukemia virus 10-like 1, homolog (mouse) 3.2 2.4
A  44 P478066 NM 001106335 Incenp Inner centromere protein 1.4 1.4
A  64 P033214 XM 346406 Top2a Topoisomerase (DNA) II alpha 1.5 1.5
A 43 P10723 XM 001080736 Bub1b Budding uninhibited by benzimidazoles 1 homolog, beta 1.7 1.4
A  44 P1045354 NM 199081 Slc35b1 Solute carrier family 35, member B1 1.9 1.3
Table 3
Common genes signiﬁcantly altered by AA in females sampled in the morning (AM) and at night (PM).
Fold Change
(p < 0.05)
Probe Name Gen bank Accession Gene Symbol Gene Name AM PM
Up-regulated
A 44 P533786 NM 053749 Aurkb Aurora kinase B 2.8 1.4
A 44 P461544 NM 001009470 Ccnb2 Cyclin B2 2.8 1.5
A  44 P534089 NM 171991 Ccnb1 Cyclin B1 2.7 1.4
A  42 P535608 NM 001107160 Asf1b ASF1 anti-silencing function 1 homolog B (S. cerevisiae) 2.6 1.4
A  44 P189375 NM 001001719 Fancd2 Fanconi anemia, complementation group D2 2.6 1.5
A  44 P381917 NM 133386 Sphk1 Sphingosine kinase 1 2.5 1.7
A  44 P223446 NM 001107873 Mcm2 Minichromosome maintenance complex component 2.4 1.4
A  44 P478066 NM 001106335 Incenp Inner centromere protein 2.3 1.4
A  44 P213149 NM 001107369 Mastl Microtubule associated serine/threonine kinase-like 2.3 1.6
A  64 P075910 NM 001101014 Ajap1 Adherens junction associated protein 1 2.2 1.6
A  64 P129618 NM 001017459 Mdm1 Mdm1 nuclear protein homolog (mouse) 2.2 1.2
A  42 P643574 NM 001106795 Aaas Achalasia, adrenocortical insufﬁciency, alacrimia (Allgrove, triple-A) 1.7 1.2
A  42 P502590 NM 001107424 Slc7a6 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 6 1.6 1.2
A  64 P097193 XM 001072207 Topbp1 Topoisomerase (DNA) II binding protein 1 1.5 1.2
Down-regulated
A  64 P008477 NM 001000247 Olr325 Olfactory receptor 325 −1.4 −1.2
A  42 P463998 NM 031013 Abcc6 ATP-binding cassette, sub-family C (CFTR/MRP), member 6 −1.5 −2.0
A  64 P029596 NM 001102417 Svs3b Seminal vesicle secretory protein 3B −1.6 −3.0
A  44 P302179 XM 001070842 Naip5 NLR family, apoptosis inhibitory protein 5 −1.6 −1.4
A  44 P612186 NM 001107344 Mylip Myosin regulatory light chain interacting protein −1.6 −1.2
A  44 P279116 XM 002726450 Dyrk4 Dual-speciﬁcity tyrosine-(Y)-phosphorylation regulated kinase 4 −1.6 −1.3
A  64 P083349 NM 021843 Kitlg KIT ligand −1.6 −1.3
A  64 P010648 NM 001105822 Ccl12 Chemokine (C-C motif) ligand 12 −1.7 −1.4
A  64 P008330 NM 001000020 Olr1454 Olfactory receptor 1454 −1.7 −1.3
A  44 P1000391 NM 001106140 Atp8b1 ATPase, Class I, type 8B, member 1 −1.8 −1.2
A  64 P050650 XM 344594 Sox4 SRY (sex determining region Y)-box 4 −1.9 −1.3
A  64 P127823 NM 001108629 Ggct Gamma-glutamyl cyclotransferase −1.9 −1.2
A  44 P684740 NM 001107279 Pcdh17 Protocadherin 17 −2.3 −1.4
A  64 P008502 NM 001109574 Tmem169 Transmembrane protein 169 −2.7 −1.5
A  43 P12257 NM 022604 Esm1 Endothelial cell-speciﬁc molecule 1 −2.9 −1.6
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Table 4
Partial list of common sub-networks signiﬁcantly affected in the thyroid gland of
male and female rats exposed to AA. Complete data are shown in Table SI-2.
Sub-networks p-value (<0.05)
Gene Set Seed Male at night Female at night Female at morning
Cell proliferation 8.3E-14 1.1E-10 9.4E-11
Cell differentiation 2.0E-11 1.9E-10 5.4E-10
Apoptosis 3.4E-10 9.2E-15 4.1E-13
Cell death 4.9E-10 7.6E-09 1.3E-07
Cell migration 6.3E-09 5.7E-06 1.2E-06
Vascularization 2.7E-08 1.7E-03 3.2E-07
Cell growth 5.0E-08 2.5E-08 6.1E-11
Cell cycle 9.2E-08 6.3E-08 9.1E-07
Pregnancy 7.3E-07 3.7E-03 2.3E-03
Oxidative stress 7.6E-07 8.6E-04 7.9E-06
Cell survival 1.7E-06 5.1E-05 1.7E-05
Endocytosis 2.3E-06 5.2E-04 4.5E-07
Heart function 4.6E-06 6.3E-03 6.9E-03
Contraction 1.4E-05 2.3E-03 4.9E-03
G2/M transition 1.7E-05 1.4E-05 2.6E-04
Morphogenesis 2.1E-05 1.9E-06 2.4E-03
Ossiﬁcation 3.6E-05 1.2E-04 1.8E-02
Inﬂammatory response 6.2E-05 4.7E-03 4.9E-03
Protein folding 2.6E-04 1.0E-03 1.5E-02























Sub-networks that were signiﬁcantly altered by AA in female rats sampled at night
(FN) or in the morning (FM) (statistically tested by Fisher’s Exact Test (p < 0.05, data
in  order of lowest p-value).
Gene Set Seed p-value (FN) p-value (FM)
Mitosis 8.05E-07 NE
Embryonal development 6.85E-06 NE
M  phase 4.61E-05 NE
Kinetochore assembly 5.01E-05 NE
Meiosis 7.94E-05 NE
Oncogenesis 1.13E-04 NE
DNA replication checkpoint 1.30E-04 NE
Macrophage differentiation 1.67E-04 NE
G2  phase 1.67E-04 NE
Genetic instability 1.99E-04 NE
G2/M checkpoint 2.60E-04 NE
Regeneration 2.83E-04 NE
Response to stress 3.52E-04 NE
Mitotic entry 4.76E-04 NE
Mitotic checkpoint 4.87E-04 NE
Muscle development 4.98E-04 NE
Fibroblast accumulation 5.22E-04 NE
Muscle regeneration 5.41E-04 NE
ER-associated protein catabolism 6.76E-04 NE
Microtubule cytoskeleton assembly 7.21E-04 NE
Erythrocyte differentiation 7.79E-04 NE
Nerve maturation 8.50E-04 NE
Xenobiotic metabolism 8.61E-04 NE
Mitotic spindle assembly 9.06E-04 NE
Chromosome condensation 1.03E-03 NE
Cell adhesion NE 1.77E-05
Mitochondrial damage NE 2.81E-05
Regulation of cell size NE 5.23E-05
Muscle cell differentiation NE 9.85E-05
Kidney function NE 1.19E-04
Glial cell response NE 1.40E-04
Cell-cell adhesion NE 1.57E-04
Adipocyte differentiation NE 1.61E-04
Wound healing NE 4.84E-04
SMC  proliferation NE 5.90E-04
Neuron apoptosis NE 6.80E-04
Luteinization NE 8.26E-04
G1  phase NE 8.44E-04
Senescence NE 8.79E-04
Actin organization NE 9.21E-04
Secretory pathway NE 1.14E-03
Endothelial cell function NE 1.15E-03
Endothelial cell proliferation NE 1.22E-03
Myocyte proliferation NE 1.26E-03
Colonization NE 1.28E-03
Arteriogenesis NE 1.39E-03
Embryo implantation NE 1.40E-03
Biomineral formation NE 1.44E-03
Autophagic cell death NE 1.65E-03
Endomitotic cell cycle NE 1.74E-03
T
C
NDNA replication 5.0E-04 8.9E-04 2.8E-03
Response to hypoxia 9.8E-04 8.9E-03 5.0E-03
RRAP/Tip60Chromatin Remodeling, mRNA Transcription and Pro-
essing, Double Strand DNA Homologous Repair, cell cycle and
NA replication, among others (Table SI-4A and 4B). There was
ood concordance between the pathways selected via SNEA and
he GSEA.
Selected pathways graphically show similarities between males
nd females sampled at night (Figs. 3–5 ).
.4. Diurnal changes in female rats sampled either at night or in
he morning.
Diurnal changes in gene expression could only be observed in
emale rats, since we had issues with the microarrays for male rats.
e observed many more changes in pathways in female rats sam-
led at night than those sampled in the morning (Table SI-4B and
C). While both groups showed changes in similar repair mech-
nisms including DNA repair, protein degradation and recycling,
hromatin remodeling, and the immune system; there were many
ore entities present in the affected pathways in animals sampled
t night than those sampled in the morning. However, among the
op pathways with the lowest P values (<0.01) by GSEA, 15 were
nly altered in females collected at night which involved methyla-
ion of histones and DNA, chromatin remodeling, mRNA and rRNA
ranscription and processing, tight junction assembly, and immune
unction, such as peptide antigen and complement pathways. One
NE; No effect.
able 6
ommon pathways identiﬁed by GSEA in the thyroid gland of male and female rats exposed to AA.
Gene Set Category: Ariadne Cell Process Pathways Male at night Female at night Female at morning
Median change p-value Median change p-value Median change p-value
DNA replication 1.3 0.01 1.1 0 1.1 0
Histone and DNA methylation 1.2 0.02 1.1 0 NE 0.01
Histone phosphorylation 1.1 0 1.1 0 1.1 0
Direct DNA repair 1.1 0.02 1.1 0 1.1 0.01
Single-strand mismatch DNA repair 1.2 0 1.1 0 1.1 0
Double strand DNA homologous repair 1.2 0 1.1 0 1.1 0
Single-strand base excision DNA repair 1.2 0.01 1.1 0 1.1 0
Cell  cycle 1.2 0 1.1 0 1.1 0
Actin  cytoskeleton assembly 1.1 0 NE 0.02 1.2 0.01
Tight  junction assembly (Occludin) 1.2 0 1.1 0.03 NE 0.01
E; No effect.










Nig. 3. Alterations in gene expression related to (A–B) spindle assembly and (C–D) ki
SNEA) (p-value > 0.05; fold change >± 1.2; by Fisher’s Exact Test) using PathwaySt
own-regulated genes; red, up-regulated genes. Abbreviations for gene names are athway was  shared by both morning and night animals, which
nvolved ubiquitin-dependent protein degradation, and 1 path-
ay was altered only in females collected in the morning and this
nvolved actin cytoskeleton assembly (Table 7).
able 7
ifferences in pathways determined by GSEA in female rats sampled at night or in the mo
Females
Gene Set Category: Night 
Ariadne Cell Process Pathways Median change 
Histone and DNA methylation 1.1 
SWI/SNF BRG1/BAF Chromatin remodeling 1.1 
SWI/SNF BRG1/PBAF Chromatin remodeling 1.1 
NURD Chromatin remodeling 1.1 
NURF  Chromatin remodeling 1.1 
CHRAC Chromatin remodeling 1.1 
SRCAP Chromatin remodeling 1.1 
Presentation of endogenous peptide antigen 1.1 
mRNA Transcription and processing 1.1 
rRNA  Transcription and processing 1.1 
Histones sumoylation 1.1 
Single-strand nucleotide excision DNA repair 1.1 
SWI/SNF BRM/BAF Chromatin remodeling 1.1 
Tight  junction assembly (Occludin) 1.1 
Classical complement pathway −1.2 
Ubiquitin-dependent protein degradation 1.1 
Actin  cytoskeleton assembly NE 
E; No effect.hore assembly. These pathways were built using sub-networks enrichment analysis
. (A, C) Male rats sampled at night; and (B, D) female rats sampled at night. Blue,
 abbreviation list.3.5. Validation of gene expression changes by qPCR
Genes implicated in cell cycle checkpoint pathways were inves-
tigated due to their presence in many of the sub-networks. There
rning (p < 0.05, data ordered by lowest p-value).
Morning

































Dig. 4. Alterations in gene expression related to reactive oxygen species (A-B) (RO
etworks enrichment analysis (SNEA) (p-value > 0.05; fold change >± 1.2; by Fisher
ats  sampled at night. Blue, down-regulated genes; red, up-regulated genes. Abbrev
s good concordance between microarray and qRT-PCR (Table 8).
nly changes in the mRNA for card 9 and TPO were signiﬁcantly
ltered (p < 0.05) in the qPCR assay when compared to controls but
he fold differences observed for microarray and qPCR for these
enes were similar. qPCR is an exponential expansion of the data
nd small pipetting errors sometimes lead to non-signiﬁcant dif-
erences being observed. We  probably needed a higher “n” for
tatistical signiﬁcance.
able 8
omparison of fold changes in mRNA steady state levels obtained from microarray and qP
tress  for male and female rats sampled in the morning and at night.
(A) Morning group Female






(B) Night group Male 
Gene Symbols Microarrays qPC
Card9 1.62a 1.6
Ddit  4 2.63a 1.4
Drd2  5.17a 5.1
Tpo  1.59a 1.9
Tnfs13 1.63a 1.6
ata are presented as mean fold changes in relative mRNA expression from control (n = 5
a signiﬁcantly altered in microarrays.
** signiﬁcantly altered in qPCR (p < 0.05). (C-D) microtubule cytoskeleton assembly. These pathways were built using sub-
t Test) using PathwayStudioTM. (A, C) Male rats sampled at night; and (B, D) female
s for gene names are in the abbreviation list.
4. Discussion
AA is known to produce thyroid gland follicular cell tumors
and mammary gland ﬁbroadenomas in Wistar rats. AA has been
classiﬁed as a genotoxic chemical because it can alkylate DNA and
cause chromosome breaks and rearrangements (clastogenic mode
of action), but only at high concentrations. In the current experi-
ment, glycidamide adducts were measured from AA [23]. Cyp2E1







































fig. 5. Genes altered by AA exposure of rats that relate to (A-B) DNA replication and 
alue  > 0.05; fold change >± 1.2; by Fisher’s Exact Test) using PathwayStudioTM. (A, C)
enes;  and red, up-regulated genes. Abbreviations for gene names are in the abbrev
s moderately expressed in the thyroid [4]. But, the active concen-
rations of glycidamide would have been quite low since we  used a
elatively low concentration of AA in a chronic exposure scenario.
e tested the hypothesis that AA would alter gene expression and
hysiological endpoints in Wistar rats at night when they are active
ore so than in the daytime, when rats are sleeping. AA and gly-
idamide have very short biological half-lives so we thought the
vening measurement would be a more sensitive indicator of AA
mmediate effects in these neonatal rats because AA and glyci-
amide would still be present in the circulation. While the overall
ene expression changes observed clearly involve DNA damage and
epair, there were also changes involving oxidative stress, cellular
otility, motor proteins such as the kinesin-related proteins, and
inases, all of which may  be causally related to genotoxicity and
ncogenicity.
.1. Phenotypic anchoring
A separate cohort of the same animals was allowed to con-
inue on the same regimen for 2 years [51]. At the end of the
wo-year period, histopathology indicated tumors of the mam-
ary gland (ﬁbroadenomas) in females and thyroid follicular
ell tumors in both sexes. No other increase of tumors was
ound. Hemoglobin adducts of acrylamide and glycidamide wereDNA repair. These pathways were built using sub-networks enrichment analysis (p-
 rats sampled at night; and (B, D) female rats sampled at night. Blue, down-regulated
 list.
measured over several timepoints throughout the 2 years and these
showed dose and time response [23], conﬁrming the exposures.
We did not check for DNA adducts, but in other studies, these
types of exposures have been shown to induce DNA adducts [74].
In addition, other non-neoplastic changes were observed includ-
ing sciatic nerve nephropathy, spinal cord degeneration and hind
limb myopathy [51]. Previous studies with rats have shown similar
thyroid follicular cell neoplasms [2,26].
The only phenotypic endpoints we  measured in the pnd 35 ani-
mals were plasma hormones. Thyroid hormones were altered only
in animals sacriﬁced at night with both males and females showing
increased plasma T3 and T4, and only females showing depressed
TSH. Normally one would expect that disruption of the HPT axis
in rodents in a manner that induces thyroid carcinogenesis would
be through increased TSH secretion that provides growth stimulus
to the thyroid gland [8]. Our results suggest that the changes in T3
and T4 were primary as opposed to secondary due to an elevation in
TSH. The decreased TSH in females might reﬂect negative feedback
suppression due to the elevated thyroid hormones.
In a study with male adult Fischer 344 rats exposed to three
concentrations of AA (2.5 mg/kg/d; 10 mg/kg/d and 50 mg/kg/d) in
their drinking water for 14 days and sacriﬁced presumably during
the day, only the highest dose of AA showed a signiﬁcant decrease
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hese authors concluded that AA did not affect hormone produc-
ion in the animals. But, critical differences exist with our study.
nimals collected in the day in our study also did not show any
peciﬁc effects in the plasma, but animals collected at night, did, as
iscussed above.
Several genes associated with thyroid function were altered
n rats in the current study that point to dysregulation of hor-
one production. The altered genes included neuropeptide Y
NPY), solute carrier family 5 (sodium iodide symporter), member
 (SLC5A5), iodotyrosine deiodinase (IYD) and thyroid stimulating
ormone receptor (TSHR) (Table SI-1). Sub-network analysis sug-
ested that thyroid hormone generation and thyroid function were
ltered in males (Fig. 2 and Table SI-2).
.2. Commonalities and differences in gene expression changes in
ales and females sampled at night and in the morning
Consistent with the known effects of AA, genes associated with
pindle and kinetochore assemblies were altered (Fig. 3). Both male
nd female night animals showed alteration of many elements
n these pathways, including three kinesins, Kif20b, Kif22, and
if2a. Kinesins are microtubule-associated motor proteins, which
re essential components for intracellular transport and cell divi-
ion [57]. There are 45 members of this superclass of proteins in
ammals and their main attribute is having a microtubule bind-
ng domain and an ATPase domain. These proteins can walk along
icrotubules to deliver cargo to the appropriate places. Kinesins
ave been associated with cancer. For example, over expression of
if2a has been associated with poor outcome for colorectal cancer
21].
Kinesins have been demonstrated to be direct targets for AA
nd glycidamide [27,53,66]. While different kinesins were studied
han the three upregulated in the current study, the fact that the
ctivity of KIFC5A and KRP2, representative of two different kinesin
amilies, could be inhibited by relatively low concentrations of AA
r glycidamide (range 100–5 mM for 60–80% inhibition), suggests
hat the entire family may  be vulnerable [66], leading to cell division
efects and potential carcinogenicity.
Interestingly, pathways involved with oxidative stress were also
rominent for night animals (Fig. 4). While ROS was  not directly
easured in this study, steady state levels of mRNAs encoding
roteins involved in this process were up-regulated. The over-
ll pathway for ROS was up-regulated in both males and females
ampled at night but down-regulated in females sampled in the
orning. ROS generation by acrylamide has been observed in other
tudies [32,46].
A similar pattern is seen for microtubule cytoskeleton assem-
ly showing up-regulation of this process in night animals but an
verall down-regulation in females sampled in the morning. Inter-
stingly, night animals showed down-regulation of genes involved
n muscle development suggesting that energy was  diverted
oward repair and detoxiﬁcation and away from general anabolic
etabolism (data not shown).
DNA repair, DNA replication, cell proliferation, checkpoint path-
ays, and apoptosis were altered by the low chronic dose of AA
mployed in the current study. Fig. 5 illustrates some of the enti-
ies that were common for DNA replication and DNA repair in males
nd females sampled at night (Fig. 5). As prognostic markers of can-
er, transcripts involved in key checkpoint pathways were altered,
ncluding inner centromere protein (Incenp), topoisomerase (DNA)
I alpha (Top2A) and budding uninhibited by benzimidazoles 1
omolog, beta (Saccharomyces cerevisiae)  (Bub1B), among others
Table 2). Transcripts involved in neurotoxicity also were affected,
or example dopamine receptor D2 (Drd2), which was  increased by
.2 (p = 0.018) fold in males and by 2.4 (p = 0.05) fold in females col-
ected at night. The role of dopamine in peripheral tissues is an areaReports 3 (2016) 414–426
of current interest [64]. Our data is consistent with the observation
that exposure to acrylamide inhibited the uptake of dopamine into
striatal synaptic vesicles of rats [1,47].
AA is a type-2 alkene, which is a soft electrophile that reacts
preferentially with nucleophilic cysteine thiolate sites of proteins,
as can be found in catalytic triads [48]. However, a low but con-
sistent reaction with the N-terminal Val group of hemoglobin has
also been observed for AA and this has been used as an effective
bioassay for acrylamide exposure [23,24,58]. In vivo, AA is metabo-
lized by CYP 2E1 to glycidamide (an epoxide), which is very reactive
toward nucleophiles and has been implicated in adduct formation
for hemoglobin and nucleic acids [23,53].
Glycidamide is also a potential source of oxidative stress. AA is
converted to glycidamide, with rates varying from organ to organ
[37]. AA can also bind to glutathione [25,29,49,70], which normally
is at high intracellular concentrations between 0.1 mM and 15 mM
[13]. While most cellular proteins would be protected by the high
GSH, the intracellular concentrations can vary depending on the
location, with the lowest intracellular ratio of GSH-GSSG measured
in the rough endoplasmic reticulum [13]. Modulation of GSH levels
by AA has been demonstrated in Syrian Hamster Embryo (SHE) cells
and is an essential occurrence for cell transformation [39].
Because AA effectively alkylates Cys residues, a low ratio of
GSH:GSSG would promote alkylation of proteins, which would be
inﬂuenced by active drinking of AA laced water. Both cysteine and
glutathione were protective of AA induced malformation in frogs
[63]. Reactivity toward Cys suggests vulnerabilities. If proteins with
active site Cys residues were adducted, this could result in enzyme
inactivation. The system would likely respond by making more
mRNA for inactivated proteins. Interestingly, in our study, we iden-
tiﬁed increased levels of mRNAs for proteins that are known to
be cysteine rich and that may  contain Cys residues in their active
sites, including cysteine-rich with EGF-like domains 2 (Creld2),
glutamate-cysteine ligase (Gclc) catalytic subunit, and selenocys-
teine lyase (Scly), which were increased by 2.2 fold and 2.1 fold;
by 2.0 and 1.4; and by 1.7 and 1.3 in male and female rats at
night, respectively (Table 2). Creld2 has been proposed as a novel
endoplasmic reticulum stress-inducible gene, associated with fold-
ing, processing and protein transport [60]. Scly is a selenoprotein
involved in cancer with its main function being protection against
an excess of ROS [6,68]. Gclc controls synthesis of GSH, the main
antioxidant in the cell [9,14,42].
It is useful to consider a model that includes adap-
tive/compensatory gene expression changes as protective action
against damage by low concentrations of AA. With chronic expo-
sure, the compensatory pathways may  not fully contain cellular
damage, unleashing a second line of defense, for example up-
regulation of apoptotic processes. At this stage of cellular assault,
one would expect to see additional pathways altered including
those involving structural proteins within the cell, since caspases
activated via apoptosis can cut spectrin and other cellular scaffold
proteins [75]. Only at higher levels of cellular damage, caused by the
conversion of AA to glycidamide, would covalent adducts be seen
with proteins and/or DNA, unleashing DNA repair and disturbing
cell cycle regulation and check point pathways [10].
Dose-response relationships between the formation of tumors
in thyroid tissues and genotoxic events suggest that other mech-
anisms in addition to genotoxicity might be involved in tumor
formation in the thyroid at low concentrations of AA [15], for exam-
ple through stimulation of thyroid cell proliferation by an alternate
mechanism. The evidence that hormones may  be involved actually
comes from studies using relatively high doses of AA, 10–50 mg/Kg
bw/d. At these high concentrations of AA, serum LH levels were
signiﬁcantly increased, while FSH, testosterone and prolactin, were
signiﬁcantly decreased in chronically dosed male rats [7]. At lower
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ncrease in T4 and a decrease of TSH levels were previously reported
36], which are in agreement with hormonal changes seen in our
tudy.
Rats are nocturnal animals and sleep during the day from 6 AM
o 6 PM [30,71]. The sampling regimen was designed to sample
ats at night when they were actively drinking water laced with AA
nd compare them to quiescent animals sampled in the morning.
n each case, the sampling occurred several hours into each phase,
t 10 PM or 10 AM.  While all animals showed alterations in genes
elated to DNA damage, there were additional altered pathways
hat appeared mainly in the night groups, suggesting that these
ere stimulated by newly introduced AA. These pathways were
elated with reactive oxygen species, oxidative stress, detoxiﬁca-
ion systems, energy production and metabolism.
The commonality among all of the AA dosed animals sug-
ests DNA damage, cell damage and cell death as the primary,
ong-term effects caused by chronic AA exposure. These ﬁndings
re consistent with other studies that point to DNA damage and
umorigenesis [11,17,26,28,38,41,50,54,61,62].
These data bear directly on the regulatory classiﬁcation of AA
s a genotoxic carcinogen. In regulatory schemes AA risk is quan-
itated as that of a genotoxic carcinogen [18,20]. However, at low
nd intermittent doses, tumorigenesis appears to be consecutive
o AA targeting key cellular proteins and their functions leading
o oxidative stress and to thyroid hormone changes, rather than
enotoxicity.
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